Abstract
Pelvic perfusion hyperthermia (PPH) for malignant gynecologic diseases in the pelvis was performed for four hours with favorable results. Serial monitoring of chemotherapeutic drug concentrations in the blood, tissues and circuit showed that the drugs were satisfactorily incorporated into the tumor bearing area and that the systemic leak was minimal with no demonstrable systemic side effects. The temperature of the tumor was kept between 41.8°C and 42.7°C for over three hours. The esophageal temperature was maintained below 40°C throught the procedure. In one patient, there was an eighty percent reduction in tumor size and in the other, a complete regression of the tumor. We conclude that the PPH is a procedure that warrants further attention as an adjunct to cancer therapy for malignant pelvic tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creech O Jr, Kremenz ET, Ryan RF, Winbald JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632.
Klopp CT, Alford TC, Beteman J, Berry GN, Winship T: Fractionated intra-arterial cancer chemotherapy with methyl bis amine hydrochloride: a preliminary report. Ann Surg 1950; 132: 811–832.
Cavaliere R, Ciocatto EC, Giovanella BC. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20: 1351–1381.
Stehlin JS, Giovanella BC, DeIpoli PD, Muenz LR, Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975; 140: 339–348.
McBride CM, McMurtrey MJ, Copeland EM, Hickey RC. Regional chemotherapy by isolation perfusion. Int Adv Surg Oncol 1978; 1: 1–9.
Kremenz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: Fourteen years clinical experience. Ann Surg 1972; 175: 900–917.
Sugarbaker EV, McBride CM. Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities. Cancer 1976; 37: 188–198.
Lathlop JC, Leone IA, Soderbert CH Jr, Colbert MP, Vargas LL. Perfusion chemotherapy for gynecological malignancy. Trans N Engl Obstet Gynecol Soc 1963; 17: 47–55.
Wile A, Juler GL, Rosenberg H, Haiduc N, Stemmer EA. Control of pelvic cancer with hyperthermic isolation-perfusion. J Surg Res 1983; 34: 560–567.
McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary for invasive malignant melanoma of the limbs. Ann Surg 1975; 182:316–324.
Karakousis CP, Kanter PM, Lopez R, Moore R, Holyoke ED. Modes of regional chemotherapy. J Surg Res 1976; 26: 131–141.
Hafström K, Jönson PE. Hyperthermic perfusion of recurrent malignant melanoma on the extremities. Acta Chir Scand 1980; 146: 313–318.
Karakousis CP, Kanter PM Park HC, Sharma SD, Moore R, Ewing JH. Tourniquet infusion versus hyperthermic perfusion. Cancer 1982; 49: 850–854.
Diodolkar MS, Kanter PM, Baffi RR, Schwartz HS, Lopez R, Baez M. Comparison of regional versus systemic chemotherapy with adriamycin. Ann Surg 1978; 187: 332–336.
Watkins E Jr, Hering AC, Luna R, Adams HD. The use of intravascular balloon catheters for isolation of the pelvic vascular bed during pump-oxygenator perfusion of cancer chemotherapeutic agents. Surg Gynecol Obstet 1960; 111: 464–468.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yokoyama, I., Yamanaka, N., Kato, N. et al. Pelvic perfusion hyperthermia for advanced pelvic malignancies. The Japanese Journal of Surgery 15, 49–54 (1985). https://doi.org/10.1007/BF02469857
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02469857